GET DAILY SIGNALSWhy Is Septerna (SEPN) Stock Down -6.47% Today?
Key Takeaways
- Shares of Septerna, Inc. fell roughly 6.47%, or $3.14, to $45.42 from the prior session's close of $48.56.
- The primary driver is profit-taking after a sharp post-earnings rally that carried the stock from about $43 to $52.34 in a matter of days.
- A soft third-quarter report — earnings and revenue both missed consensus — remains an overhang on sentiment.
- The decline tracked broader biotech-sector weakness, with the sector benchmark trading lower alongside the stock.
- The pullback is the second straight down session following a 7.22% slide in the prior session, on above-average volume.
- For deeper data on valuation and expectations, explore the Price Targets, Earnings, and Forecast pages.
- Interested in AI-driven market insight? Discover the Trending AI Robots curated for current conditions.
Opening Summary
SEPN — Septerna, Inc., a clinical-stage biotechnology company headquartered in South San Francisco that pioneers oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) — is trading sharply lower in Tuesday's session. The stock is down approximately 6.47% to $45.42, versus the prior close of $48.56. The decline extends a pullback that began in the previous session, as investors lock in gains following a powerful rally sparked by third-quarter earnings and a wave of bullish analyst commentary.
Profit-Taking After a Post-Earnings Rally
The clearest explanation for today's move is simple profit-taking. SEPN surged from roughly $43 in early November to an intraday peak of $53.34 — a gain of more than 20% in just over a week — after the company reported third-quarter results and multiple Wall Street analysts raised their price targets. When a low-float, high-beta biotech name rallies that quickly, momentum traders and short-term holders often step in to bank gains, and that unwinding appears to be driving the current selling pressure.
A Soft Third-Quarter Report Lingers
Beneath the surface, the fundamentals that sparked the rally were mixed. SEPN posted a third-quarter loss of $0.57 per share, wider than the $0.45 consensus estimate, on revenue of $18.88 million that also missed expectations of roughly $20.78 million. Revenue declined about 12% year over year, and the company swung to a net loss compared with a year-ago profit. Management emphasized a strong cash position of roughly $565 million and a clinical pipeline advancing toward key milestones, but the earnings and revenue shortfall has given sellers a reason to take a more cautious stance as the initial enthusiasm fades.
Sector-Wide Biotech Weakness
Today's decline is also occurring within a broadly softer biotechnology tape. The sector benchmark XBI is trading down roughly 3% on the session, reflecting a risk-off tilt across clinical-stage and small-cap drug developers. In this environment, extended names like SEPN, which had already delivered outsized gains, are especially vulnerable to de-risking as investors rotate toward more defensive positioning.
Market Context and Trading Activity
The move is unfolding on meaningfully elevated volume, consistent with heavy distribution rather than a quiet drift. The prior session saw turnover of roughly 1.13 million shares — more than two and a half times the 30-day average — and today's decline continues that trend of above-normal activity. Technically, the stock has given back a meaningful portion of its recent surge, breaking back below the $48–$50 zone that had acted as short-term support, with attention now turning to whether buyers emerge near the high-$40s or the low-$40s range where the rally initially launched.
What Comes Next for SEPN
Looking ahead, SEPN remains a catalyst-driven story. Investors are watching for Phase 1 data from its PTH1R agonist SEP-479, expected in the first quarter of 2027, as well as the planned initiation of a Phase 1 trial for its newly selected oral TSHR candidate SEP-204 in the same timeframe. The company's substantial cash runway — expected to support operations at least into 2029 — reduces near-term financing risk, but the stock's elevated volatility and sensitivity to clinical news remain key uncertainties. Given the recent run and rapid unwind, near-term direction will likely hinge on whether sector sentiment stabilizes and whether buyers step back in ahead of the next pipeline readouts.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and traded symbols, but only the top performers are featured in this section. Explore the page to see which strategies are adapting to today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SEPN turns positive, indicating new upward trend
SEPN saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator turned positive. In 27 of the 28 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SEPN just turned positive on October 20, 2026. Looking at past instances where SEPN's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.
SEPN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SEPN crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 89 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 100 of 118 cases where SEPN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for SEPN moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 16 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
SEPN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.896) is normal, around the industry mean (3.498). SEPN has a moderately low P/E Ratio (-92.170) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (17.361) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement